GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications
Cerasus Journal of Medicine · 31.05.2026 · 3 (2) · 157-164
DOI: 10.70058/cjm.1924573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cerasus Journal of Medicine, online erschienen am 31.05.2026. Verfasst von Turan Kaan Karakaya und 1 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Gefördert von: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Abstract (Originalsprache)
Objective
To evaluate the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on metabolic parameters, hormonal profiles, and reproductive outcomes in the preconception management of women with polyendocrine metabolic ovarian syndrome (PMOS) and obesity.
Methods
A comprehensive literature search was conducted across scientific databases, including PubMed/MEDLINE, Scopus, and Web of Science, focusing on clinical trials, reviews, and guidelines published between January 2022 and April 2026. Studies evaluating the efficacy, safety, tolerability, and economics aspects of GLP-1 RAs used alone or combined with metformin in obese PMOS phenotypes were systematically analyzed.
Results
GLP-1 RAs demonstrate favorable clinical efficacy compared to conventional lifestyle modifications and metformin in reducing body weight and visceral adiposity. By addressing the adipose-androgen crosstalk and mitigating low-grade chronic inflammation, GLP-1 RAs improve insulin sensitivity and reduce compensatory hyperinsulinemia. This metabolic optimization promotes increased hepatic sex hormone-binding globulin (SHBG) synthesis and decreased circulating free testosterone levels, facilitating the restoration of regular menstrual cycles and spontaneous ovulation. Combination therapy of GLP-1 RAs with metformin yields robust synergistic effects, though consideration of higher treatment costs is warranted. Due to limited definitive data on fetal safety during early pregnancy exposure, a strict pre-pregnancy washout period remains mandatory.
Conclusion
GLP-1 RAs offer a promising, multisystemic therapeutic strategy for the preconception management of PMOS with obesity, effectively breaking the cycle of insulin resistance and hyperandrogenemia. While providing profound metabolic and reproductive benefits, strict adherence to preconception discontinuation protocols is essential. Future large-scale randomized controlled trials are required to further clarify optimal dosing, long-term safety, and definitive gestational outcomes.
Förderung
- This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors
Zitieren
APA
Karakaya, T. K., & Yılmaz, S. (2026). GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications. Cerasus Journal of Medicine, 3(2), 157-164. https://doi.org/10.70058/cjm.1924573
Vancouver
Karakaya TK, Yılmaz S. GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications. Cerasus Journal of Medicine. 2026;3(2):157-164. doi:10.70058/cjm.1924573
BibTeX
@article{Karakaya2026,
author = {Karakaya, Turan Kaan and Yılmaz, Sercan},
title = {GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications},
journal = {Cerasus Journal of Medicine},
year = {2026},
volume = {3},
number = {2},
pages = {157--164},
doi = {10.70058/cjm.1924573}
}
EUVIMED